Non-Alcoholic Steatohepatitis (NASH) Pipeline Review, H2 2017, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/351502 .
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis (NASH) Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 28, 27, 3, 75, 28 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Browse the full report @ http://www.orbisresearch.com/reports/index/non-alcoholic-steatohepatitis-nash-pipeline-review-h2-2017 .
Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/351502 .
Reasons to buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Albireo Pharma Inc
Alnylam Pharmaceuticals Inc
Amunix Operating Inc
Aquinox Pharmaceuticals Inc
Arcturus Therapeutics Inc
Bird Rock Bio Inc
BLR Bio LLC
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd
Carmot Therapeutics Inc
Catabasis Pharmaceuticals Inc
Cerenis Therapeutics Holding SA
Conatus Pharmaceuticals Inc
Connexios Life Sciences Pvt Ltd
ConSynance Therapeutics Inc
CymaBay Therapeutics Inc
Daiichi Sankyo Company Ltd
Dimerix Bioscience Pty Ltd
Dong-A Socio Holdings Co Ltd
Dynavax Technologies Corp
Eli Lilly and Company
Enanta Pharmaceuticals Inc
Foresee Pharmaceuticals LLC
Forma Therapeutics Inc
Galectin Therapeutics Inc
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc
Gilead Sciences Inc
GRI Bio Inc
Hanmi Pharmaceuticals Co Ltd
iCo Therapeutics Inc.
Intercept Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Matinas BioPharma Holdings Inc
Merck & Co Inc
Mitochon Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
NeuroVive Pharmaceutical AB
NGM Biopharmaceuticals Inc
Nippon Chemiphar Co Ltd
Nordic Bioscience A/S
NovaTarg Therapeutics Inc
Novo Nordisk A/S
Ocera Therapeutics Inc
Promethera Biosciences SA
ProMetic Life Sciences Inc
Protalix BioTherapeutics Inc
Redx Pharma Plc
Regulus Therapeutics Inc
Saje Pharma LLC
Sancilio & Company Inc
Seres Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Sprint Bioscience AB
TaiwanJ Pharmaceuticals Co Ltd
Tiziana Life Sciences Plc
TRACON Pharmaceuticals Inc
Translate Bio Inc
Vascular Biogenics Ltd
Verlyx Pharma Inc
Viking Therapeutics Inc
Zydus Cadila Healthcare Ltd
For any enquires before buying, connect with us @ email@example.com
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact firstname.lastname@example.org